



**Nirav S. Patel, M.D.**  
Apex Innovative Sciences  
Collaborative Neuroscience Research, LLC  
Collaborative Neuroscience Network, LLC  
2600 Redondo Avenue, Suites 415 & 500  
Long Beach, CA 90806

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, VP Sponsor Relations/BD  
Apex Innovative Sciences, Alliance Division  
Tel. 916-803-7149 (cell)  
Email: [bobbietheodore@apexsci.com](mailto:bobbietheodore@apexsci.com)

**AFFILIATIONS:**

Collaborative Neuroscience Research, LLC  
Collaborative Neuroscience Network, LLC  
12772 Valley View Street, Suite 3  
Garden Grove, CA 92845

Department of Neurology  
David Geffen School of Medicine at UCLA  
300 UCLA Medical Plaza, Suite B200  
Los Angeles, CA 90095

Collaborative Neuroscience Research, LLC  
Collaborative Neuroscience Network, LLC  
19401 S. Vermont Avenue, Suite F-100  
Torrance, CA 90502

Southland Neurologic Associates, Inc.  
3851 Katella Ave. Ste 215  
Los Alamitos, CA, 90720

Ocean View Psychiatric Health Facility  
2600 Redondo Avenue, Suite 500  
Long Beach, CA 90806

Southland Neurologic Associates, Inc.  
3747 Worsham Ave. Ste 100  
Long Beach, CA, 90808

Long Beach Memorial Medical Center  
2801 Atlantic Avenue  
Long Beach, CA 90806

Los Alamitos Medical Center  
3751 Katella Ave  
Los Alamitos, CA 90720

Community Hospital of Long Beach  
1720 N. Termino Ave  
Long Beach, California 90804

Harbor-UCLA Medical Center  
1000 W. Carson Street  
Torrance, California 90502

Lakewood Regional Medical Center  
3700 East South Street  
Lakewood, CA 90712

Orange Coast Memorial Medical Center  
9920 Talbert Avenue  
Fountain Valley, CA 92708

**AFFILIATIONS (continued):**

Saddleback Memorial Medical Center  
24451 Health Center Drive  
Laguna, CA 92653

Fountain Valley Regional Center  
17100 Euclid Street  
Fountain Valley, CA 92708

**EDUCATION:**

1992 Doctor of Medicine  
University of California at Los Angeles School of Medicine, Los Angeles, CA

1989 Bachelor of Science in Biomedical Sciences  
University of California at Riverside, Riverside, CA

1985-1992 Biomedical Sciences Accelerated Program, University of California at Riverside and  
University of California at Los Angeles, Los Angeles, CA

**INTERNSHIPS, FELLOWSHIPS AND RESIDENCIES:**

1996-1997 Stroke Fellowship  
Harbor-UCLA Medical Center, Torrance, CA

1996 Transcranial Doppler and Cerebral Blood Flow laboratory  
University of California at Los Angeles, Los Angeles, CA

1993-1996 Neurology Residency (Adult)  
Harbor-UCLA Medical Center, Torrance, CA

1992-1993 Internal Medicine Internship  
Harbor-UCLA Medical Center, Torrance, CA

**CERTIFICATIONS:**

Certified by the American Board of Psychiatry and Neurology in Neurology

National Board of Medical Examiners Part I and Part II

**LICENSURE:**

Licensed Physician and Surgeon, State of California, License No. G79448

**PROFESSIONAL EXPERIENCE:**

*Investigator*, 2019 - Present  
Apex Innovative Sciences

*Investigator*, 2007 – Present  
Collaborative Neuroscience Network, LLC, Long Beach, CA  
Collaborative Neuroscience Network, LLC, Long Beach, CA

*Medical Director of Stroke Services*, Nov 2014 - Present  
Lakewood Regional Medical Center, Lakewood, CA

*Medical Director of Stroke Services, Chairman*, 2008 – Present  
Department of Medicine, Los Alamitos Medical Center, Los Alamitos, CA

*Private Practice*, 2004 – Present  
Southland Neurologic Associates, Los Alamitos, CA

*Assistant Clinical Professor*, 2003  
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA

*Clinical Faculty*, 1997 – Present  
Department of Neurology, Harbor-UCLA Medical Center, Torrance, CA

*Adult Primary Care Nurse Practitioner Program Faculty*, 1997 - 2003  
Harbor-UCLA Medical Center, Los Angeles, CA

*Department of Family Medicine Faculty*, 1999-2000  
School of Osteopathy, Pacific Hospital of Long Beach, CA

*Biomedical Program Faculty*, 1998-2002  
Neuroscience class, University of California at Riverside, CA

**INVESTIGATOR EXPERIENCE:**

Phase I-IV: Alzheimer's Disease • Chronic Pain • Cognition • Dementia  
Diabetic Peripheral Neuropathy • Epilepsy • Migraine • Multiple Sclerosis • Neuropathic Pain  
Osteoarthritis • Osteoporosis • Parkinson's Disease • Post-Herpetic Neuralgia  
Restless Legs Syndrome • Schizophrenia • Spasticity • Stroke/ Post-Stroke

**ADDITIONAL TREATMENT EXPERIENCE:**

Fibromyalgia • Insomnia

**CLINICAL TRIAL EXPERIENCE:**

***Phase I Studies***

A Phase Ib, Open-label Study to Describe the Pharmacokinetics and Safety-Tolerability of a Single Oral Dose of XXX Administered to Adult Women and Men Experiencing Moderate to Severe Migraine Headache

A Phase I, Randomized, Open-label, Fixed Sequence, 2-Period, Comparative Bioavailability Study of XXX Solution when Administered to Migraine Subjects as Nasal Spray During a Migraine Attack versus a Non-Migraine Period

A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple-Dose Pharmacokinetics and Pharmacodynamics of XXX in Patients with Relapsing Multiple Sclerosis

A Phase I Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of XXX in Subjects with Multiple Sclerosis Immediately Following a Relapse

A Phase I, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of XXX in Patients with Multiple Sclerosis

A Phase I, Multi-center, Open-Label Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Intravenous XXX in subjects with Multiple Sclerosis

***Phase II-IV Studies***

***Alzheimer's Disease***

A 24 Week Open-Label Extension to Study XXX A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION)

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Efficacy And Safety Trial Of XXX in Patients With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein E 4 Non-Carriers Carriers

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

***Epilepsy***

A Phase III Study that is Analyzing the Effectiveness and Safety of XXX injections for patients with epilepsy that receive antiepileptic drugs, but still experience acute repetitive seizures (bouts or clusters of seizures) that require treatment

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of XXX Controlled Release Formulation as Adjunctive Therapy in Adult Subjects with Partial onset Seizures

A Phase III, Multi-center, Open-Label Study Designed to Assess the Safety and Tolerability of Intravenously Administered XXX in Adult Subjects with Epilepsy. This Study will Include a 28-day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28-day Follow-up Period

A Phase III Study that is Analyzing the Effectiveness and Safety of XXX Injections for Patients with Epilepsy that Receive Antiepileptic Drugs, but Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) that Require Treatment

A Double-Blind, Randomized, Historical-Controlled, Multi-Center Efficacy and Safety Study of XXX as Monotherapy in Patients with Refractory Partial Seizures & An Open-Label Multi-Center Extension Study to Determine Long Term Safety and Efficacy of XXX as Monotherapy in Patients With Partial Seizures

A Conversion to Monotherapy for Adults with Epilepsy Experiencing Partial Seizures (with or without Secondary Generalization), A Historical-controlled, Multi-center, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs to be Managed by XXX to Evaluate the Safety and Efficacy of an Investigational Product as Monotherapy in Subjects with Partial Epilepsy Unresponsive to Current Antiepileptic Drugs (AED) in Comparison to Historical- Pseudo -Placebo Control Groups

A Study of Long-Term Safety and Efficacy of XXX as Monotherapy in Patients with Partial Seizures

***Migraine***

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of XXX intranasal (IN) for the Acute Treatment of Migraine

A Phase III, 12-Month Study to Evaluate the Safety and Tolerability of XXX (Nasal Powder) in the Acute Treatment of Migraine

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase II/III Open-label, Long-Term, Safety Trial of XXX Intranasal (IN) for the Acute Treatment of Migraine

A Phase II: Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial of XXX for the Acute Treatment of Migraine

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of XXX Nasal Powder in the Acute Treatment of Migraine

A Phase III, Multicenter, Randomized, Open-label Study to Evaluate the Longterm Safety and Tolerability of Oral XXX for the Prevention of Migraine in Patients with Episodic Migraine

A Phase III, Randomized, Double blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention

A Phase III, Open-label Study of Safety and Tolerability of Chronic Intermittent Usage of XXX Nasal Spray Administered by the XXX device in Patients With Migraine Headache over 26/52 weeks.

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of XXX Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase II Study to Assess the Safety, Tolerability, and Efficacy of XXX Delivered as an Intranasal Spray for Preventive Treatment in Subjects with Episodic Migraine

A Phase IIa, Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention

A Multicenter, Open Label, Long-Term Safety Study of XXX in Patients with Acute Migraines

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral XXX in the Acute Treatment of Migraine With or Without Aura

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety and Tolerability of Oral XXX in the Acute Treatment of Migraine

An Observational Research Study: Prospective Cohort Study to Describe Patient-Reported Outcomes in Subjects with Migraine Eligible for Prophylaxis

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Administered Intravenously in Patients with Chronic Migraine

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Four-Treatment, Three-Period Crossover Study Evaluating Efficacy of a Single Dose of XXX in Patients with Migraine Headache with or without aura

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention

A Randomized, Multicenter, Double-Blind, Placebo Controlled, Two-Arm Study Evaluating Efficacy of a Single Dose XXX (10 mg vs. Placebo) in Patients with Acute Migraine Headache With or Without Aura

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Episodic Migraine Prevention, Dosed monthly by subcutaneous (SC) injection

A Phase II Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study of XXX for Migraine Prophylaxis in Patients with Migraine

A Phase II, Safety, Tolerability, and Efficacy Study of XXX in the Treatment of Acute Migraine Headache

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of XXX Versus XXX-Containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Pain Phase of the Migraine

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of XXX in Adult Migraineurs

A XXX Migraine Study: 2000

***Multiple Sclerosis***

A Phase IIIb, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Higher Dose of XXX in Adults with Relapsing Multiple Sclerosis

A Phase III, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of XXX Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of XXX Compared with XXX, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety followed by OLE

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of XXX with an Active Control Group Interferon Beta 1a XXX, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

A Phase III Multicenter, Open-Label Safety and Efficacy Study of XXX Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment

A Phase III, 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of XXX Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment

A Phase III, Open-Label Study to Evaluate the Long-Term Safety of XXX Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity

A Phase III, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of XXX Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis

A Phase III XXX In Multiple Sclerosis Treatment Effects XXX Study. A 120 week, Phase III, randomized, multi-center, double-blinded, double-dummy, active-controlled study that is primarily designed to assess the ARR and safety/ tolerability of XXX as compared to XXX placebo in subjects with RMS

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of XXX as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

A Phase III Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of XXX and XXX

A Phase III, Open Label Study to Evaluate the Long-term Safety and Tolerability of XXX in Subjects with Relapsing Remitting Multiple Sclerosis

A Phase III, Open-label study to Assess the Effects of XXX on lymphocyte subsets in subjects with relapsing-remitting multiple sclerosis

A Phase III, multi-site, open-label extension trial of oral XXX in relapsing multiple sclerosis



**CLINICAL TRIAL EXPERIENCE (continued):**

A Phase III, Multi-center, Randomized, Double-blind, Double-dummy, Active controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXX Administered Orally to Relapsing Multiple Sclerosis Patients

A Multicenter, treatment blind Phase IIIb study to evaluate whether 6 week up-titration in XXX dose is effective in reducing the Incidence of Gastro-Intestinal adverse events in relapsing-remitting Multiple Sclerosis patients

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of XXX on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

A Phase II/III, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of XXX Administered Orally to Relapsing Multiple Sclerosis Patients

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of XXX Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of XXX in Subjects with Spasticity due to Multiple Sclerosis

A Phase III, Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Increasing Doses of XXX Extended Release Tablets to Placebo and XXX Tablets, for the Treatment of Spasticity in Patients with Multiple Sclerosis

A Phase II, randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of XXX on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis

A Phase III, Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of XXX 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects with Relapsing-Remitting Multiple Sclerosis

A Phase III, Open Label, 26-Week Study Assessing XXX Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis with an Addendum Open-Label, 36-Week Study Assessing XXX Safety in Subjects with Spasticity Associated with Multiple Sclerosis

An Open Label, 26-Week Study Assessing XXX Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Spasticity due to Multiple Sclerosis

A Multicenter, Observational, Open-Label, Single-Arm Study of XXX in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral XXX Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX

MS (multiple sclerosis) Trak Study: 1999

***Osteoarthritis***

A Randomized, Placebo-Controlled Trial of XXX Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Moderate to Severe, Chronic Knee or Hip Pain From Osteoarthritis

***Pain***

A Phase II, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX in the Treatment of Diabetic Peripheral Neuropathic Pain

A Phase II, Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Diabetic Peripheral Neuropathic Pain

A Multicenter, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of XXX in Subjects with Type 2 Diabetes and Diabetic Peripheral Neuropathy

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Assessing the Efficacy, Safety and Tolerability of XXX for the Pain of Diabetic Peripheral Neuropathy

**CLINICAL TRIAL EXPERIENCE (*continued*):**

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of XXX 20MG and 120MG Twice Daily for 4 Weeks in Patients with Chronic Peripheral Neuropathic Pain

A Phase II, 52-week, Open-label, Long-term Treatment Evaluation of the Safety and Efficacy of XXX in subjects with moderate to severe Chronic Pain

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Diabetic Painful Neuropathy and Small Fiber Neuropathy Associated with Impaired Glucose Tolerance Followed by a Double-Blind Safety Extension and an Open Label Safety Extension

A Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of XXX on Reduction of Pain from Vertebral Fracture Associated with Osteoporosis  
An Open-label, Multi-center Trial to Assess the Long-term Safety and Efficacy of XXX in Opioid-experienced Subjects with Chronic Non-cancer Pain

A 12-week Placebo-Controlled, Double-Blind, Randomized withdrawal Study to Evaluate the Efficacy and Safety of XXX in Subjects with Moderate to Severe Chronic Low Back Pain

A Randomized Withdrawal, Multi-center, Open-Label, Multiple-Dose, Long-Term Safety Study  
Randomized, Open-Label, Parallel-Group, Multiple-Dose, Long-Term Safety Study in Subjects with Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

A Phase IIb Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy

A Randomized, center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of XXX Vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia

A Phase II Randomized, Double Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effect of XXX in Adult Patients with Chronic Low Back Pain

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Comparing the Analgesic Efficacy and the Safety of XXX (1 Mg, 2 Mg, And 4 Mg), XXX (60 Mg) and Placebo in Approximately 275 Subjects with Diabetic Neuropathic Pain

**CLINICAL TRIAL EXPERIENCE (*continued*):**

***Parkinson's Disease***

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Parkinson's Disease

A Randomized, Double-Blind, 2-Way Crossover Study to Compare XXX to Standard Carbidopa-Levodopa and Characterization of Multiple-dose Pharmacokinetics and Pharmacodynamics of XXX in Levodopa-experienced Parkinson's Disease Subjects with Motor Complications

***Stroke/ Post-stroke***

A Phase III, Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of XXX Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the XXX Study

A Phase III, Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of XXX Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the XXX Study

A Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor XXX (110 mg or 150 mg, Oral b.i.d.) Versus XXX (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of XXX Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke

A Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of XXX in the treatment of post-stroke spasticity of the lower limb

KEEPER Study: 2001

Saviant Study (Prosopride): 2003

Fast-MAG Trial. An NIH-NIND-Sponsored clinical Trial to Evaluate Field Initiation of Magnesium Neuroprotective Therapy in Acute Stroke. The FAST-MAG Phase 3 trial is a multicenter, randomized, placebo-controlled, double-blind, parallel group trial of intravenous magnesium sulfate initiated by paramedics in the field within 2 hours of symptom onset in 1700 patients with acute stroke. The primary objective of the study is to evaluate the efficacy and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.

**CLINICAL TRIAL EXPERIENCE (*continued*):**

***Other Indications***

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of XXX Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

A Phase II, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of XXX in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)

A Fixed Dose Randomized, Double-Blind, 12-week Study of XXX Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of XXX in Stable Patients with Schizophrenia

**PRESENTATIONS AND GUEST LECTURES:**

Stroke, Poster Presentation: Title: Evolution of a U.S. County System for Acute Comprehensive Stroke Care, Topic: Emergency Care Systems, Number: WP273 - 2017 - International Stroke Conference, February 22, 2017

Stroke, Resident Lecture Series, Department of Family Medicine, Pacific Hospital of Long Beach: 1998; 1999

Neurology Lecture Series, St. Mary Medical Center Long Beach: 1997-2002

Stroke, Resident Lecture, Department of Family Medicine, Harbor-UCLA Medical Center: 1997

Neurology Consultant, Morbidity & Mortality Conference, Department of Internal Medicine, Harbor-UCLA Medical Center, 1996; 1997

Epilepsy, Resident Lecture series, Department of Family Medicine, Harbor-UCLA Medical Center: 1996

Stroke, 1996 Board Review Course for the Examination for Added Qualifications in Geriatric Psychiatry, California Geriatric Education Center, UCLA Multi-campus Program in Geriatric Medicine and Gerontology: 1996

Neurology Clinical Cases, 1996 Board Review for the Examination for Added Qualifications in Geriatric Psychiatry, California Geriatric Education Center, UCLA Multi-campus Program in Geriatric Medicine and Gerontology, 1996

Epilepsy, Transitional Internship Lecture Series, Harbor-UCLA Medical Center 1996

**VOLUNTARY SERVICE:**

Chancellor Place at Chino Hills, Assisted Living and Retirement facility, 2003 to present  
St. Mary Medical Center Senior Center: 2000-2004  
Pio Pica Elementary School, Santa Ana, Health Day, 2000  
Los Angeles Marathon, Physician Volunteer: 1995, 1996, 1997  
B.A.P.S. Swaminarayan Hindu Temple, Medical Services for the Community: 1990-2004  
American Red Cross, Blood Donation Drive: 1990; 1991; 1992  
Big Brothers of Greater Los Angeles: 1995-1997

**MEMBERSHIPS:**

American Academy of Neurology, Active member: 1995 to present  
Association of California Neurologists, Active member: 2001-2002  
Los Angeles Society of Neurological Sciences, Active member; 1996 to present, former board member  
Los Angeles County Medical Association, Associate member: 1995 to present  
American Heart Association, Long Beach, board member: 2000-2001  
Joint Council of Interns & Residents, executive board member, USC, Harbor-UCLA, Martin Luther King, Secretary/Treasurer: 1996-1997, Vice President: 1995-1996  
Joint Council of Interns & Residents, Harbor-UCLA Medical Center, President: 1995-1997  
Vice President: 1994-1995, Neurology representative: 1993-1997

**SPECIAL HONORS:**

Teaching Recognition Award, Internal Medicine Residency Program, St. Mary Medical Center affiliated with UCLA School of Medicine: 1998, 1999, 2001, and 2002  
Outstanding Teaching Attending, Internal Medicine Residency Program St. Mary Medical Center affiliated with UCLA School of Medicine; 1997  
Teaching Excellence Award, UCR/UCLA Biomedical Science Program, Harbor-UCLA Medical Center: 1997  
Honor Award for support of resident issues, Joint Council of Interns & Residents: 1999  
Chief Resident, Department of Neurology, Harbor-UCLA Medical Center: 1995-1996  
Graduated Cum Laude, Baccalaureate of Science, Biomedical Sciences, UC Riverside: 1989  
Dean's List, UC Riverside: 1985-1989  
Bank of America Award, Mathematics: 1985  
Hollywood High School Alumni Scholarship: 1985